Glen Eagle Advisors’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.8K | Hold |
150
| – | – | ﹤0.01% | 909 |
|
|
2026
Q1 | $1.26K | Hold |
150
| – | – | ﹤0.01% | 901 |
|
|
2025
Q4 | $2.16K | Hold |
150
| – | – | ﹤0.01% | 877 |
|
|
2025
Q3 | $1.45K | Hold |
150
| – | – | ﹤0.01% | 950 |
|
|
2025
Q2 | $1.23K | Hold |
150
| – | – | ﹤0.01% | 904 |
|
|
2025
Q1 | $1.07K | Hold |
150
| – | – | ﹤0.01% | 922 |
|
|
2024
Q4 | $1.16K | Hold |
150
| – | – | ﹤0.01% | 947 |
|
|
2024
Q3 | $1.57K | Hold |
150
| – | – | ﹤0.01% | 940 |
|
|
2024
Q2 | $1.75K | Hold |
150
| – | – | ﹤0.01% | 919 |
|
|
2024
Q1 | $3.16K | Hold |
150
| – | – | ﹤0.01% | 850 |
|
|
2023
Q4 | $2.69K | Hold |
150
| – | – | ﹤0.01% | 830 |
|
|
2023
Q3 | $2.47K | Hold |
150
| – | – | ﹤0.01% | 831 |
|
|
2023
Q2 | $3K | Hold |
150
| – | – | ﹤0.01% | 813 |
|
|
2023
Q1 | $2.84K | Hold |
150
| – | – | ﹤0.01% | 804 |
|
|
2022
Q4 | $3.4K | Hold |
150
| – | – | ﹤0.01% | 778 |
|
|
2022
Q3 | $3.96K | Hold |
150
| – | – | ﹤0.01% | 745 |
|
|
2022
Q2 | $3.71K | Hold |
150
| – | – | ﹤0.01% | 750 |
|
|
2022
Q1 | $4.98K | Hold |
150
| – | – | ﹤0.01% | 714 |
|
|
2021
Q4 | $4.91K | Hold |
150
| – | – | ﹤0.01% | 714 |
|
|
2021
Q3 | $6.29K | Hold |
150
| – | – | ﹤0.01% | 784 |
|
|
2021
Q2 | $5.83K | Hold |
150
| – | – | ﹤0.01% | 792 |
|
|
2021
Q1 | $5.12K | Hold |
150
| – | – | ﹤0.01% | 765 |
|
|
2020
Q4 | $6.8K | Hold |
150
| – | – | ﹤0.01% | 690 |
|
|
2020
Q3 | $4.13K | Hold |
150
| – | – | ﹤0.01% | 718 |
|
|
2020
Q2 | $5.53K | Sell |
150
-100
| -40% | -$3.73K | ﹤0.01% | 652 |
|
|
2020
Q1 | $8.1K | Sell |
250
-200
| -44% | -$8.33K | 0.01% | 547 |
|
|
2019
Q4 | $18.4K | Hold |
450
| – | – | 0.01% | 476 |
|
|
2019
Q3 | $16K | Hold |
450
| – | – | 0.01% | 437 |
|
|
2019
Q2 | $23.1K | Buy |
450
+107
| +31% | +$5.34K | 0.02% | 386 |
|
|
2019
Q1 | $19.7K | Hold |
343
| – | – | 0.01% | 387 |
|
|
2018
Q4 | $14.4K | Hold |
343
| – | – | 0.01% | 409 |
|
|
2018
Q3 | $25.9K | Buy |
343
+93
| +37% | +$6.7K | 0.02% | 337 |
|
|
2018
Q2 | $17.9K | Hold |
250
| – | – | 0.01% | 375 |
|
|
2018
Q1 | $7.46K | Buy |
+250
| New | +$7.28K | 0.01% | 474 |
|
Other funds holding RGNX
RG
Glen Eagle Advisors's RGNX Position: Q2 2026 in Review
Glen Eagle Advisors held its Regenxbio (RGNX) position steady in Q2 2026 at 150 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #909.
Glen Eagle Advisors first reported a position in RGNX in Q1 2018 and has held it in 34 quarters since. The position peaked at $25.9K in Q3 2018. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- Glen Eagle Advisors held 150 shares of Regenxbio worth $1.8K as of Q2 2026.
- Glen Eagle Advisors left its Regenxbio share count unchanged in Q2 2026.
- Regenxbio made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #909 holding.
- Glen Eagle Advisors first reported a position in Regenxbio in Q1 2018 and has held it in 34 quarters since.
- Glen Eagle Advisors's Regenxbio position peaked at $25.9K in Q3 2018.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.